{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:19:00Z","timestamp":1788265140800,"version":"build-2803163510"},"reference-count":39,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>Fluoroquinolones (FQs) are the cornerstone in treating drug-resistant tuberculosis (TB); the prevalence of TB among the population is diverse in different regions, understanding the relationship between resistance pattern and molecular characteristic of FQs in preextensive drug-resistant (pre-XDR) clinical isolates is limited in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A total of 141 pre-XDR clinical isolates from different individuals stored at the National Clinical Centre were collected from the Beijing Chest Hospital, minimal inhibitory concentrations of levofloxacin (Lfx) and moxifloxacin (Mfx) as well as sequences of quinolone-resistant determining regions in\n                      <jats:italic toggle=\"yes\">gyrA<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">gyrB<\/jats:italic>\n                      genes were examined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      One hundred twelve pre-XDR clinical isolates were resistant to both Lfx and Mfx, molecular analyses showed that 87.50%, 0.89%, and 6.25% of the pre-XDR clinical isolates harbored FQ resistance mutations in\n                      <jats:italic toggle=\"yes\">gyrA<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">gyrB<\/jats:italic>\n                      , and in both. We found five amino acid mutation positions in\n                      <jats:italic toggle=\"yes\">gyrA<\/jats:italic>\n                      and four in\n                      <jats:italic toggle=\"yes\">gyrB<\/jats:italic>\n                      , The mutation position in\n                      <jats:italic toggle=\"yes\">gyrA<\/jats:italic>\n                      included codons 94, 91, 90, 88, and 74, and in\n                      <jats:italic toggle=\"yes\">gyrB<\/jats:italic>\n                      included codons 504, 500, 512, and 501. Codon 94 of\n                      <jats:italic toggle=\"yes\">gyrA<\/jats:italic>\n                      was the most prevalent mutation (83.04%), containing the Asp amino acid substitution with Gly (50.89%), Asn (15.17%), Ala (8.93%), Tyr (6.25%), and His (1.79%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      The mutations of\n                      <jats:italic toggle=\"yes\">gyrA<\/jats:italic>\n                      were most common and the frequency of Asp94Gly was the highest in pre-XDR clinical isolates in Beijing, China. The mutations at codon 94 significantly contributed to the resistance to both Lfx and Mfx in pre-XDR clinical isolates and may cause a high resistance level.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/mdr.2021.0212","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T09:25:42Z","timestamp":1641288342000},"page":"280-287","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular Characteristic of Both Levofloxacin and Moxifloxacin Resistance in\n                    <i>Mycobacterium tuberculosis<\/i>\n                    from Individuals Diagnosed with Preextensive Drug-Resistant Tuberculosis"],"prefix":"10.1177","volume":"28","author":[{"given":"Xiaofu","family":"Zhang","sequence":"first","affiliation":[{"name":"Beijing Chest Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fu","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmin","family":"Huo","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhui","family":"Gao","sequence":"additional","affiliation":[{"name":"Beijing Chest Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6803-9807","authenticated-orcid":false,"given":"Yu","family":"Pang","sequence":"additional","affiliation":[{"name":"Biobank of Tuberculosis, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lu","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Center on Tuberculosis Control, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"World Health Organization. 2020. Compendium of TB\/COVID-19 studies. Geneva: World Health Organization. Available at https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/covid-19\/compendium (accessed July29 2020)."},{"key":"e_1_3_4_3_2","unstructured":"World Health Organization. 2015. Digital health for the End TB Strategy: an agenda for action (WHO\/HTM\/TB\/2015.21). Geneva: WHO. Available at https:\/\/www.who.int\/tb\/publications\/digital health-TB-agenda\/en\/ (accessed July29 2020)."},{"key":"e_1_3_4_4_2","unstructured":"World Health Organization. 2018. Global tuberculosis control report 2018. WHO\/CDS\/TB\/2018.20. Available at https:\/\/www.who.int\/tb\/publications\/global report\/en\/ (accessed February11 2019)."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.104-112.2006"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MGM2-0009-2013"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31644-1"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0959"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01257-15"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep25330"},{"key":"e_1_3_4_11_2","first-page":"1990","volume":"56","author":"Pantel A.","year":"2012","unstructured":"Pantel A., , Petrella S., , Veziris N., et al. 2012. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob. Agents Chemother. 56:1990\u20131996.","journal-title":"Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob. Agents Chemother"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012245"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2014.21"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00662-15"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01947-09"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00197-11"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.4.773"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00177-09"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01550-10"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00287-09"},{"key":"e_1_3_4_21_2","first-page":"5427","article-title":"Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis","volume":"49","author":"Willby M.","unstructured":"Willby M., , David Sikes R., , Malik S., et al. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:5427\u20135434.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks033"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00425-16"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2014.61"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S200697"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2018.06.014"},{"key":"e_1_3_4_27_2","first-page":"69","article-title":"Performance of sequencing in predicting ofloxacin resistance in Mycobacterium tuberculosis from positive Bactec MGIT960 cultures","volume":"48","author":"Wang Z.","year":"2018","unstructured":"Wang Z., , Xie T., , Mu C., et al. 2018. Performance of sequencing in predicting ofloxacin resistance in Mycobacterium tuberculosis from positive Bactec MGIT960 cultures. Ann. Clin. Lab. Sci. 48:69\u201374.","journal-title":"Ann. Clin. Lab. Sci"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2020.0240"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00670-16"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2010.05.001"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki353"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-78"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-78"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06860-11"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03087.x"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.18.9869"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.443-450.2002"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00050-09"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2016.09.012"},{"key":"e_1_3_4_40_2","first-page":"596","article-title":"Global Tuberculosis Report 2019","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. 2019. Global Tuberculosis Report 2019. WHO, Geneva, Switzerland, pp. 596\u2013601.","journal-title":"WHO, Geneva,"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2021.0212","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2021.0212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2021.0212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:39:43Z","timestamp":1777667983000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2021.0212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,1]]}},"alternative-id":["10.1089\/mdr.2021.0212"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2021.0212","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}